Abstract
Nelfinavir (Viracept®) was originally designed as a specific HIV protease inhibitor and, since its introduction in 1997, has served as an effective, reliable, and well-tolerated HIV drug. Although nelfinavir is being increasingly displaced by second generation HIV protease inhibitors that allow better combination treatments, it has again become a focus of interest due to an interesting paradoxical effect: nelfinavir inhibits experimentally-induced tissue degeneration or cell damage by preventing loss of the mitochondrial membrane potential, and even protects mitochondria in cancer cells but, conversely, it selectively induces a mitochondria-independent cell death mechanism in cancer cells by the so-called endoplasmic reticulum/unfolded protein stress response, allowing nelfinavir to act on otherwise chemo-resistant cancer cells. Furthermore, anti-microbial effects of nelfinavir have been described, including an efficacy against malaria, tuberculosis, and SARS, mostly by cross-reacting with microbial aspartic proteases. Several cancer-related clinical studies on nelfinavir as a single agent or in combination therapies have been launched and are expected to add to the usefulness of this versatile drug for cancer treatment strategies or other purposes.
Keywords: Nelfinavir, HIV, protease inhibitor, cancer, endoplasmic reticulum, apoptosis, mitochondria
Current Molecular Pharmacology
Title: New Prospects for Nelfinavir in Non-HIV-Related Diseases
Volume: 3
Author(s): Ansgar Bruning, Andrea Gingelmaier, Klaus Friese and Ioannis Mylonas
Affiliation:
Keywords: Nelfinavir, HIV, protease inhibitor, cancer, endoplasmic reticulum, apoptosis, mitochondria
Abstract: Nelfinavir (Viracept®) was originally designed as a specific HIV protease inhibitor and, since its introduction in 1997, has served as an effective, reliable, and well-tolerated HIV drug. Although nelfinavir is being increasingly displaced by second generation HIV protease inhibitors that allow better combination treatments, it has again become a focus of interest due to an interesting paradoxical effect: nelfinavir inhibits experimentally-induced tissue degeneration or cell damage by preventing loss of the mitochondrial membrane potential, and even protects mitochondria in cancer cells but, conversely, it selectively induces a mitochondria-independent cell death mechanism in cancer cells by the so-called endoplasmic reticulum/unfolded protein stress response, allowing nelfinavir to act on otherwise chemo-resistant cancer cells. Furthermore, anti-microbial effects of nelfinavir have been described, including an efficacy against malaria, tuberculosis, and SARS, mostly by cross-reacting with microbial aspartic proteases. Several cancer-related clinical studies on nelfinavir as a single agent or in combination therapies have been launched and are expected to add to the usefulness of this versatile drug for cancer treatment strategies or other purposes.
Export Options
About this article
Cite this article as:
Bruning Ansgar, Gingelmaier Andrea, Friese Klaus and Mylonas Ioannis, New Prospects for Nelfinavir in Non-HIV-Related Diseases, Current Molecular Pharmacology 2010; 3 (2) . https://dx.doi.org/10.2174/1874467211003020091
DOI https://dx.doi.org/10.2174/1874467211003020091 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Multi-Target Antitubercular Drugs
Current Topics in Medicinal Chemistry Targeted Drug Delivery Systems for Lung Macrophages
Current Drug Targets Lacticin 3147 - Biosynthesis, Molecular Analysis, Immunity, Bioengineering and Applications
Current Protein & Peptide Science PEGylated Dendritic Architecture for Development of a Prolonged Drug Delivery System for an Antitubercular Drug
Current Drug Delivery Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Current Cancer Therapy Reviews Using NMR to Develop New Allosteric and Allo-Network Drugs
Current Drug Discovery Technologies Natural Products Containing Olefinic Bond: Important Substrates for Semi-synthetic Modification Towards Value Addition
Current Organic Chemistry Principles and Practices of Pathway Modelling
Current Bioinformatics QSAR and Docking Studies on Propenone Derivatives as Dual COX and 5- LOX Inhibitors
Letters in Organic Chemistry Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics Lactoferrin as a Natural Immune Modulator
Current Pharmaceutical Design Synthesis and In Vitro Antibacterial Screening of some New 2,4,6-Trisubstituted-1,3,5-Triazine Derivatives
Letters in Drug Design & Discovery New Agents for the Treatment of Tuberculosis on Clinical Study Phases II/III
Current Respiratory Medicine Reviews HLA-DR: Molecular Insights and Vaccine Design
Current Pharmaceutical Design Recent Advances in Medicinal Chemistry to Treat Tuberculosis – Part-I
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Searching a New Antibiotic Prototype: Snake Venoms)
Mini-Reviews in Organic Chemistry Antimicrobial Effects of Chemical Compounds Isolated from Traditional Chinese Herbal Medicine (TCHM) Against Drug-Resistant Bacteria: A Review Paper
Mini-Reviews in Medicinal Chemistry Current Applications of the Sonogashira Reaction in the Synthesis of Heterocyclic Compounds: An Update
Current Organic Chemistry Current and Future Chemotherapy for Chagas Disease
Current Medicinal Chemistry